Generic Name and Formulations:
Nicotine 7mg/24hr, 14mg/24hr, 21mg/24hr; transdermal patch.
Dr. Reddy's Laboratories, Inc.
Indications for HABITROL:
Adjunct in smoking cessation therapy.
≥18yrs: Apply to clean, dry, nonhairy site on trunk or upper outer arm; rotate application site. Remove patch after 24 hours; if vivid dreams or other sleep disturbances occur, remove at bedtime and reapply in AM. >10cigarettes/day: initially one 21mg patch daily for 4 weeks; then one 14mg patch daily for 2 weeks, then one 7mg patch daily for 2 weeks, then stop. ≤10cigarettes/day: initially one 14mg patch daily for 6 weeks then one 7mg patch daily for 2 weeks, then stop. Max 1 patch/24hrs. Do not cut patch.
<18yrs: not recommended.
Concurrent smoking or use of other nicotine products.
Discontinue if irregular heartbeat, palpitations, allergic reaction, or symptoms of nicotine overdose occur. Heart disease. Post-MI. Arrhythmias. Hypertension. Depression. Asthma. Allergy to adhesive tape, other skin problems. Stomach ulcers. Diabetes. History of seizures. Low doses may be toxic to children and pets; discard properly. Pregnancy: not recommended. Nursing mothers.
Remove patch prior to MRI procedures. Smoking cessation potentiates theophylline, insulin, β-blockers, pentazocine, oxazepam, tricyclic antidepressants (eg, imipramine), caffeine, acetaminophen, adrenergic antagonists (eg, prazosin, labetalol), others. Smoking cessation antagonizes adrenergic agonists (eg, isoproterenol, phenylephrine), others.
Local irritation, GI upset, headache, dizziness, palpitations, hypertension.
Patch 7mg, 14mg—7, 14; 21mg—7, 14, 28
Neurology Advisor Articles
- The Consequences of Compensation in Autism
- Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis
- Novel Therapy May Improve Symptoms in Early Huntington Disease
- Interaction of Alcohol, Smoking on Multiple Sclerosis Severity
- Demoralization Common in Patients With Parkinson Disease
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- Migraine a Common Comorbidity in Individuals With Sarcoidosis
- Cardiovascular Risk Factors and Development of Brain Atrophy in Multiple Sclerosis
- Association Between Multiple Sclerosis Relapses and Vaccinations
- Understanding Impulse Control Disorders in Parkinson Disease: Developments and Treatments